NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization148.98 mln
Float46.25 mln
Earnings Date05/13/2026
EPS
0.39
Marginal
P / E
6.92
Undervalued
Piotroski F-Score
8
/ 9
Very strong
1-Year Forecast
9.86
Transformational upside
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
0.17
Very low leverage
Business Description
Black Diamond Therapeutics is a Cambridge, Massachusetts-based drug development company working to create targeted cancer treatments for patients whose tumors are driven by specific genetic mutations. Its most advanced drug, silevertinib, is currently being tested in two Phase 2 trials for lung cancer and brain tumors, while two additional compounds targeting other cancer-causing genetic changes are progressing through earlier stages of development. Founded in 2014, the company's approach centers on building treatments broad enough to address a wide range of related mutations within a given cancer type, rather than targeting a single genetic variant.
